TITLE

Antiplatelet Therapy for Every Diabetic Person?

AUTHOR(S)
NICOLUCCI, ANTONIO; STANDL, EBERHARD
PUB. DATE
May 2011
SOURCE
Diabetes Care;May2011 Supplement 2, Vol. 34, pS150
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article examines the advantages and disadvantages of aspirin use in people with diabetes. Due to indirect evidence from trials of populations who are at high risk of cardiovascular (CV) events, aspirin is recommended for the prevention of CV events in people with diabetes. One disadvantage of aspirin use is its association with high risk of intracranial and gastrointestinal bleeding. In the pros section, one trial revealed that aspirin use has reduced the risk of primary composite end point by 20 percent. One of which is peripheral arterial disease.
ACCESSION #
61968003

 

Related Articles

  • Association of Aspirin Use With Major Bleeding in Patients With and Without Diabetes. De Berardis, Giorgia; Lucisano, Giuseppe; D'Ettorre, Antonio; Pellegrini, Fabio; Lepore, Vito; Tognoni, Gianni; Nicolucci, Antonio // JAMA: Journal of the American Medical Association;6/6/2012, Vol. 307 Issue 21, p2286 

    The article discuses the association of aspirin use with major bleeding in patients with and without diabetes. It informs that aspirin is used for the treatment of cardiovascular disease and is generally recommended as a secondary prevention measure for individuals with moderate to high risk of...

  • Aspirin for primary prevention of stroke in individuals without cardiovascular disease—A meta-analysis. Judge, Conor; Ruttledge, Sarah; Murphy, Robert; Loughlin, Elaine; Gorey, Sarah; Costello, Maria; Nolan, Aoife; Ferguson, John; Halloran, Martin O; O'Canavan, Michelle; O'Donnell, Martin J // International Journal of Stroke;Jan2020, Vol. 15 Issue 1, p9 

    Background: The benefits of aspirin for primary prevention of stroke are uncertain. Methods: We performed a cumulative meta-analysis of trials investigating aspirin for primary prevention of cardiovascular disease with a focus on stroke. We assessed the effects of aspirin on non-fatal stroke,...

  • Aspirin use and risk for bleeding in primary prevention. Taylor, James R. // Endocrine Today;Aug2012, Vol. 10 Issue 8, p48 

    The author discusses recommendations issued by the American Diabetes Association (ADA) regarding aspirin use in diabetic patients and recently published research which suggests link between aspirin use and gastrointestinal or cerebral bleeding.

  • Low-dose aspirin is associated with an increased risk of haemorrhage; but not in people with diabetes who have a high baseline rate of bleeding. Butalia, Sonia; Leung, Alexander A. // Evidence Based Nursing;Apr2013, Vol. 16 Issue 2, p55 

    The article presents a cohort study to demonstrate an association between low-dose aspirin risk of haemorrhage. The study was conducted on adults and used poisson regression to estimate adjusted incidence rate ratios (IRRs) to compare individuals exposed and non-exposed to aspirin. The findings...

  • Aspirin use in cardiovascular disease should be abandoned.  // Practice Nurse;11/20/2009, Vol. 38 Issue 9, p7 

    The article reports that analysis of the evidence taken from a Drug and Therapeutics Bulletin (DTB) study shows that the risks of gastrointestinal bleeding outweigh the benefits of taking aspirin to prevent heart and circulatory disease. Low-dose aspirin is prescribed as prophylaxis for people...

  • Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. Derry, Sheena; Loke, Yoon Kong // BMJ: British Medical Journal (International Edition);11/11/2000, Vol. 321 Issue 7270, p1183 

    AbstractObjectives: To assess the incidence of gastrointestinal haemorrhage associated with long term aspirin therapy and to determine the effect of dose reduction and formulation on the incidence of such haemorrhage.Design: Meta-analysis of 24 randomised controlled trials (almost 66 000...

  • How much aspirin is just enough?  // Cortlandt Forum;Jun2007, Vol. 20 Issue 6, p13 

    The article focuses on the therapeutic dosage of aspirin for the prevention of cardiovascular disease (CVD) in Lexington, Kentucky. It is stated that the clinical data support the administration of 75-81 milligrams per day of aspirin and higher doses are associated with the increased risk of...

  • ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use Abraham, Neena S; Hlatky, Mark A; Antman, Elliott M; Bhatt, Deepak L; Bjorkman, David J; Clark, Craig B; Furberg, Curt D; Johnson, David A; Kahi, Charles J; Laine, Loren; Mahaffey, Kenneth W; Quigley, Eamonn M; Scheiman, James; Sperling, Laurence S; Tomaselli, Gordon F // American Journal of Gastroenterology;Dec2010, Vol. 105 Issue 12, p2533 

    The article discusses the use of proton pump inhibitors (PPI) and thienopyridines as an alternative treatment for cardiovascular (CV) diseases. It says that clopidogrel is more effective than aspirin in reducing main CV events. It mentions the greater risk for gastrointestinal (GI) bleeding in...

  • Individualised prediction of alternate-day aspirin treatment effects on the combined risk of cancer, cardiovascular disease and gastrointestinal bleeding in healthy women. van Kruijsdijk, Rob C. M.; Visseren, Frank L. J.; Ridker, Paul M.; Dorresteijn, Johannes A. N.; Buring, Julie E.; der Graaf, Yolanda van; Cook, Nancy R. // Heart;Mar2015, Vol. 101 Issue 5, p369 

    Background: The value of aspirin in primary prevention of cancer and cardiovascular disease (CVD) remains unclear. The aim of this study was to identify women who benefit from alternate-day aspirin with regard to all relevant outcomes, including cancer, CVD and major gastrointestinal bleeding....

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics